Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

Allogene Therapeutics announced the publication of Phase 1 results for ALLO-316, an allogeneic CAR T therapy targeting CD70 in metastatic renal cell carcinoma (RCC). The TRAVERSE study demonstrated a confirmed response rate of 31% in patients with high CD70 expression, with durable remissions persisting 8 to over 18 months and manageable safety pro…

Progressive Reports June 2026 Results

Progressive Reports June 2026 Results

The Progressive Corporation announced its financial results for June 2026, showing increases in net premiums written and earned, alongside a small rise in net income for the quarter. Despite a 31% decline in monthly net income compared to prior year, the quarterly net income improved 4%. The company maintained growth in policies in force across per…

Eos Energy Enterprises Announces Preliminary Second Quarter 2026 Financial Results, Expects Record Quarterly Revenue and Backlog, and Sets Second Quarter 2026 Conference Call Date

Eos Energy Enterprises Announces Preliminary Second Quarter 2026 Financial Results, Expects Record Quarterly Revenue and Backlog, and Sets Second Quarter 2026 Conference Call Date

Eos Energy Enterprises announced preliminary Q2 2026 financial results showing record quarterly revenue between $68 million and $69 million, driven by a threefold increase in shipments and a backlog growth to approximately $807 million. The company began commercial production on its second battery line, expanding capacity and setting the stage for …

Biogen Appoints Michael J. Parini as Chief Legal Officer

Biogen Appoints Michael J. Parini as Chief Legal Officer

Biogen Inc. has appointed Michael J. Parini as its new Chief Legal Officer, effective August 3, 2026. Parini brings over 20 years of legal and biopharmaceutical industry leadership experience, including roles at Spur Therapeutics, Vertex Pharmaceuticals, and Pfizer. He will oversee Biogen's global legal and compliance functions, contributing to the…

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

VivoSim Labs, Inc. reported receiving a $5 million milestone payment from Eli Lilly linked to the advancement of a drug acquired from VivoSim's inflammatory bowel disease program. The company projects over 500% revenue growth in fiscal year 2027 driven by strong customer adoption of its innovative NAM-based 3D human cellular models for preclinical …

Kratos Opens New 167,000-Square-Foot Manufacturing Facility in Pennsylvania, Expanding Existing Footprint in the State

Kratos Opens New 167,000-Square-Foot Manufacturing Facility in Pennsylvania, Expanding Existing Footprint in the State

Kratos Defense & Security Solutions has opened a new 167,000-square-foot manufacturing facility in York, Pennsylvania, expanding its existing operations to support critical national security programs including hypersonic systems, missile defense, radar, and counter-unmanned aircraft systems. The company plans to invest over $7 million in new manufa…

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026

aTyr Pharma announced subgroup analysis from their Phase 3 EFZO-FIT study showing clinically meaningful improvements in lung function and multiple patient-reported outcomes in pulmonary sarcoidosis patients with restrictive lung disease treated with 5.0 mg/kg efzofitimod. The company submitted a protocol to the FDA for a targeted Phase 3 study focu…

Greenland Mines Reports 36–44% PdEq Grade Uplift and +31% Increase in Indicated PdEq Ounces at its Skaergaard Gold, Palladium, Platinum Project in First S-K 1300 Technical Report Summary

Greenland Mines Reports 36–44% PdEq Grade Uplift and +31% Increase in Indicated PdEq Ounces at its Skaergaard Gold, Palladium, Platinum Project in First S-K 1300 Technical Report Summary

Greenland Mines Ltd announced a substantial upgrade to its Skaergaard precious and critical metals project mineral resource estimate under the SEC's new S-K 1300 reporting standards. The updated 2026 Mineral Resource Estimate shows a 31% increase in indicated PdEq ounces and a 36% uplift in grade compared to the 2022 baseline, supported by improved…

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MediciNova, Inc. announced reaching the target enrollment of 200 patients in the NIH-funded SEANOBI-ALS study assessing their investigational drug MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS). The Expanded Access Program provides treatment to patients ineligible for other trials, marking a significant milestone in patient engagement. …

Sunrun Announces Date for Second Quarter 2026 Earnings Report

Sunrun Announces Date for Second Quarter 2026 Earnings Report

Sunrun Inc., a leading US provider of home solar and battery storage solutions, announced that it will release its second quarter 2026 earnings report after market close on August 5, 2026, followed by a conference call to discuss the results. The company offers home energy systems with a no-upfront-cost subscription model and contributes to grid st…

Anthony Petrazzuoli Joins Provident Bank as Senior Vice President, Deposit & Payments Operations Director

Anthony Petrazzuoli Joins Provident Bank as Senior Vice President, Deposit & Payments Operations Director

Provident Bank has announced the hiring of Anthony Petrazzuoli as Senior Vice President, Deposit & Payments Operations Director. Bringing over 25 years of banking experience, Petrazzuoli will oversee deposit and payment operations to enhance customer experience, regulatory compliance, and strategic initiatives supporting the bank's growth. His prio…

Top KingWin Ltd. Announces Trading Ticker Symbol Change to “DPU”

Top KingWin Ltd. Announces Trading Ticker Symbol Change to “DPU”

Top KingWin Ltd., a Cayman Islands holding company operating in China and the U.S., announced that effective July 16, 2026, its Class A ordinary shares will trade under the new ticker symbol 'DPU' on the Nasdaq Capital Market, replacing the previous symbol 'WAI'. No shareholder action is required, and the CUSIP number remains unchanged. The company…

AFC Commits $7 Million to a Senior Credit Facility

AFC Commits $7 Million to a Senior Credit Facility

Advanced Flower Capital Inc. (Nasdaq: AFCG) has committed $7 million to a $25 million senior secured credit facility aimed at refinancing existing capital and supporting growth through acquisitions in a leading outpatient behavioral health platform. The credit facility has a four-year term, is secured by all assets of the borrower, and demonstrates…

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Rani Therapeutics announced positive initial results from its Phase 1a clinical trial of RT-114, an orally administered GLP-1/GLP-2 dual agonist for obesity treatment delivered via their RaniPill® Capsule. The oral dose achieved over 150% systemic exposure compared to a matched subcutaneous injection, with no serious adverse events and mild treatme…